Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-04 04:30:05 - browse：66

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Surprise medical billing ban raises prices elsewhere

hotspot

entertainment

WSS

Abridge raises $150m as clinical notes automation market heats up

Drinking water from half of US faucets contains PFAS: Study

FDA warns medical device makers about rise in fabricated data

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Rare Northern Lights show in US this week: Where and how to see it

Medicare Advantage enrollment grows 7.1% to 33.4 million people

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Activists slam private health insurers over coverage restrictions

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

United colonoscopy coverage change 'may cost lives,' doctors say

US intelligence assessment says Iran not currently developing nuclear weapons

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Walensky prepares to leave CDC — and Congress — behind

With fresh data, a dynamic duo powers Eli Lilly to new heights

Heart attack and stroke risk calculators need revising

Hospitals are piloting generative AI tools as regulators play catch

knowledge

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

FDA warns medical device makers about rise in fabricated data

New CMS data security rules will hurt Medicare, Medicaid research

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

hotspot

entertainment

entertainment

explore